IP Library › Granted Patent US 12,442,005
Granted Patent B2
US 12,442,005 · App. 18/330,356 · Granted Oct 14, 2025

Artificial nucleic acid molecules for improved protein expression

Inventors: Andreas Thess (Kusterdingen, DE); Thomas Schlake (Gundelfingen, DE); Stefanie Grund (Stuttgart, DE)
Assignee: CureVac SE
C12N15/67A61K39/12A61K39/145A61K39/205C12N15/68C12N15/85A61K2039/53A61K2039/54A61K2039/575A61K48/00C12N2760/16134C12N2760/16171C12N2760/20134C12N2760/20171C12N2830/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,442,005
App. No.
18/330,356
Granted
Oct 14, 2025
Kind
B2
Abstract

The invention relates to a method for stimulating an immune response by intramuscular injection of an artificial nucleic acid molecule comprising an open reading frame encoding an antigen and a 3′-UTR comprising at least two poly(A) sequences. The method may yield an increased immune response to the antigen or an increased neutralizing antibody response to the antigen.

Claims (48)

1. A method for stimulating an immune response in an organism, the method comprising administering to the organism, by intramuscular injection, a RNA molecule comprising:

a) a 5′-cap structure;

b) at least one open reading frame (ORF) encoding an antigen; and

c) a heterologous 3′-untranslated region (3′-UTR) comprising at least a first and a second poly(A) sequence, wherein:

(i) the first poly(A) sequence comprises at least 20 adenine nucleotides; and

(ii) the second poly(A) sequence comprises at least 60 adenine nucleotides,

wherein the first and the second poly(A) sequences are separated by a linker nucleic acid sequence comprising at least 3 consecutive nucleotides that are not adenine nucleotides,

wherein when the RNA molecule is administered intramuscularly to the organism, the RNA molecule yields increased expression of the antigen encoded by the at least one open reading frame in comparison to the expression from a reference nucleic acid molecule comprising an identical nucleic acid sequence as the RNA molecule but lacking the linker nucleic acid sequence.

2. The method of claim 1 , wherein the second poly(A) sequence comprises at least 70 adenine nucleotides.

3. The method of claim 2 , wherein the heterologous 3′-UTR comprises, from 5′ to 3′, (i) the first poly(A) sequence; (ii) the linker nucleic acid sequence; and (iii) the second poly(A) sequence.

4. The method of claim 3 , wherein the second poly(A) sequence is located at the 3′ terminus of the RNA molecule.

5. The method of claim 4 , wherein the linker nucleic acid sequence comprises at least 5 consecutive nucleotides having no more than 2 consecutive adenine nucleotides.

6. The method of claim 5 , wherein the second poly(A) sequence comprises 100 adenine nucleotides.

7. The method of claim 5 , wherein the RNA molecule comprises a heterologous 5′ UTR sequence.

8. The method of claim 7 , wherein the RNA molecule is a mRNA molecule and wherein the linker nucleic acid sequence consists of 10 consecutive nucleotides having no more than 2 consecutive adenine nucleotides.

9. The method of claim 5 , wherein the RNA molecule is a bicistronic RNA.

10. The method of claim 5 , wherein the RNA molecule is a viral vector RNA.

11. The method of claim 5 , wherein the at least one ORF encoding the antigen has a G/C content that is increased by at least 15 percentage points relative to a corresponding reference ORF encoding the antigen.

12. The method of claim 5 , wherein the antigen is a tumor antigen.

13. The method of claim 5 , wherein the antigen is from a pathogen associated with an infectious disease.

14. The method of claim 13 , wherein the antigen is a viral antigen.

15. The method of claim 14 , wherein the viral antigen is from influenza virus, respiratory syncytial virus, herpes simplex virus, human papilloma virus, human immunodeficiency virus, dengue virus, cytomegalovirus, hepatitis B virus, rabies virus, coronavirus or yellow fever virus.

16. The method of claim 15 , wherein the viral antigen is an influenza virus antigen.

17. The method of claim 16 , wherein the influenza virus antigen is a HA antigen.

18. The method of claim 16 , wherein the RNA molecule is a mRNA molecule and wherein the linker nucleic acid sequence consists of 10 consecutive nucleotides having no more than 2 consecutive adenine nucleotides.

19. The method of claim 15 , wherein the viral antigen is a coronavirus antigen.

20. The method of claim 5 , wherein the RNA molecule is complexed with a cationic carrier or a polycationic carrier.

21. The method of claim 20 , wherein the cationic or the polycationic carrier comprises a cationic lipid.

22. The method of claim 21 , wherein the RNA molecule is transfected into cells of the organism in a nanoparticle.

23. The method of claim 22 , wherein when the RNA molecule is administered intramuscularly to the organism, the RNA molecule yields an increased immune response to the antigen encoded by the at least one open reading frame in comparison to an immune response generated by the reference nucleic acid molecule comprising the identical nucleic acid sequence as the RNA molecule but lacking the linker nucleic acid sequence.

24. The method of claim 23 , wherein when the RNA molecule is administered intramuscularly to the organism, the RNA molecule yields an increased neutralizing antibody response to the antigen encoded by the at least one open reading frame in comparison to a neutralizing antibody response generated by the reference nucleic acid molecule comprising the identical nucleic acid sequence as the RNA molecule but lacking the linker nucleic acid sequence.

25. The method of claim 22 , wherein the RNA molecule is a bicistronic RNA.

26. The method of claim 25 , wherein the antigen is an influenza virus HA antigen.

27. The method of claim 25 , wherein the antigen is a coronavirus antigen.

28. The method of claim 22 , wherein the RNA molecule is a viral vector RNA.

29. The method of claim 22 , wherein the RNA molecule comprises at least one nucleotide analog comprising a modified form of uridine chemically altered by methylation.

30. The method of claim 29 , wherein the RNA molecule is a mRNA molecule and wherein the linker nucleic acid sequence comprises at least 10 consecutive nucleotides having no more than 2 consecutive adenine nucleotides.

31. The method of claim 30 , wherein the antigen is an influenza virus HA antigen.

32. The method of claim 30 , wherein the antigen is a coronavirus antigen.

33. The method of claim 30 , wherein the first poly(A) sequence consists of 25 to 85 adenine nucleotides.

34. The method of claim 33 , wherein the RNA molecule is a mRNA molecule and wherein the linker nucleic acid sequence consists of 10 consecutive nucleotides having no more than 2 consecutive adenine nucleotides.

35. The method of claim 33 , wherein the at least one ORF is at least partially codon optimized.

36. The method of claim 33 , wherein the first poly(A) sequence consists of 30 adenine nucleotides.

37. The method of claim 36 , wherein the second poly(A) sequence consists of 70 adenine nucleotides.

38. The method of claim 21 , wherein the RNA molecule is a mRNA molecule and wherein the linker nucleic acid sequence consists of 10 consecutive nucleotides having no more than 2 consecutive adenine nucleotides.

39. The method of claim 5 , wherein the at least one ORF is at least partially codon optimized.

40. The method of claim 5 , wherein the first poly(A) sequence consists of 25 to 85 adenine nucleotides.

41. The method of claim 40 , wherein the second poly(A) sequence consists of 100 adenine nucleotides.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 25, 2023
From: CUREVAC SE
To: DEFENSE ADVANCED RESEARCH PROJECTS AGENCY
Reel/Frame 064369/0267 →
Priority Claims (1)
WO PCT/EP2014/003334 · Dec 12, 2014 · international
Continuity (5)
Division 17713533 · Apr 5, 2022
Division 17542430 · Dec 5, 2021
Division 17408332 · Aug 20, 2021
Division 15534496
Related Publication 20230313207A1 · Oct 5, 2023
References Cited (400)
US 8217016B2 · Hoerr et al. · 2012 [cited by applicant]
US 8383340B2 · Ketterer et al. · 2013 [cited by applicant]
US 8691966B2 · Kariko et al. · 2014 [cited by applicant]
US 8703906B2 · Baumhof et al. · 2014 [cited by applicant]
US 8968746B2 · Baumhof et al. · 2015 [cited by applicant]
US 9155788B2 · Hoerr et al. · 2015 [cited by applicant]
US 9226959B2 · Kramps et al. · 2016 [cited by applicant]
US 9234013B2 · Thess et al. · 2016 [cited by applicant]
US 9314535B2 · Baumhof et al. · 2016 [cited by applicant]
US 9352028B2 · Barner et al. · 2016 [cited by applicant]
US 9402887B2 · Probst et al. · 2016 [cited by applicant]
US 9421255B2 · Baumhof et al. · 2016 [cited by applicant]
US 9433669B2 · Hoerr et al. · 2016 [cited by applicant]
US 9433670B2 · Hoerr et al. · 2016 [cited by applicant]
US 9439956B2 · Hoerr et al. · 2016 [cited by applicant]
US 9447431B2 · Thess et al. · 2016 [cited by applicant]
US 9463228B2 · Hoerr et al. · 2016 [cited by applicant]
US 9572874B2 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 9616084B2 · Mutzke · 2017 [cited by applicant]
US 9623095B2 · Kallen et al. · 2017 [cited by applicant]
US 9655955B2 · Hoerr et al. · 2017 [cited by applicant]
US 9669089B2 · Thess et al. · 2017 [cited by applicant]
US 9683233B2 · Thess · 2017 [cited by applicant]
US 9688729B2 · Kramps et al. · 2017 [cited by applicant]
US 9737595B2 · Lorenz et al. · 2017 [cited by applicant]
US 9839697B2 · Thess et al. · 2017 [cited by applicant]
US 9890391B2 · Thess et al. · 2018 [cited by applicant]
US 9907862B2 · Baumhof et al. · 2018 [cited by applicant]
US 9974845B2 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 10010592B2 · Thess et al. · 2018 [cited by applicant]
US 10017826B2 · von der Mülbe et al. · 2018 [cited by applicant]
US 10047375B2 · Thess · 2018 [cited by applicant]
US 10080809B2 · Thess · 2018 [cited by applicant]
US 10111967B2 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 10111968B2 · Thess et al. · 2018 [cited by applicant]
US 10117920B2 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 10150797B2 · Kramps et al. · 2018 [cited by applicant]
US 10166283B2 · Thess et al. · 2019 [cited by applicant]
US 10172935B2 · Kallen et al. · 2019 [cited by applicant]
US 10188748B2 · von der Mülbe et al. · 2019 [cited by applicant]
US 10232024B2 · Thess et al. · 2019 [cited by applicant]
US 10293058B2 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 10293060B2 · Baumhof · 2019 [cited by applicant]
US 10307472B2 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 10369216B2 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 10434154B2 · Probst et al. · 2019 [cited by applicant]
US 10434158B2 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 10441653B2 · Hoerr et al. · 2019 [cited by applicant]
US 10501768B2 · Eber et al. · 2019 [cited by applicant]
US 10517827B2 · Eber et al. · 2019 [cited by applicant]
US 10568958B2 · Baumhof et al. · 2020 [cited by applicant]
US 10568972B2 · von der Mülbe et al. · 2020 [cited by applicant]
US 10588959B2 · Kallen et al. · 2020 [cited by applicant]
US 10596252B2 · Kallen et al. · 2020 [cited by applicant]
US 10610605B2 · Thess et al. · 2020 [cited by applicant]
US 10648017B2 · Wochner · 2020 [cited by applicant]
US 10653768B2 · Mutzke et al. · 2020 [cited by applicant]
US 10653799B2 · Thess et al. · 2020 [cited by applicant]
US 10682406B2 · Thess et al. · 2020 [cited by applicant]
US 10682426B2 · Schnee et al. · 2020 [cited by applicant]
US 10711315B2 · von der Mülbe et al. · 2020 [cited by applicant]
US 10729654B2 · Eber et al. · 2020 [cited by applicant]
US 10729761B2 · Kallen et al. · 2020 [cited by applicant]
US 10738306B2 · Thess · 2020 [cited by applicant]
US 10751424B2 · Baumhof et al. · 2020 [cited by applicant]
US 10760070B2 · Funkner et al. · 2020 [cited by applicant]
US 10780054B2 · Ketterer et al. · 2020 [cited by applicant]
US 10799577B2 · Thess et al. · 2020 [cited by applicant]
US 10799602B2 · Baumhof · 2020 [cited by applicant]
US 10837039B2 · Wochner et al. · 2020 [cited by applicant]
US 10869935B2 · Fotin-Mleczek et al. · 2020 [cited by applicant]
US 10898584B2 · Schlake et al. · 2021 [cited by applicant]
US 10898589B2 · Thess et al. · 2021 [cited by applicant]
US 10912826B2 · Thess et al. · 2021 [cited by applicant]
US 10918740B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 10988754B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 11034729B2 · Kramps et al. · 2021 [cited by applicant]
US 11078247B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 11110156B2 · Thess et al. · 2021 [cited by applicant]
US 11110157B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 11110166B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 11135312B2 · von der Mülbe et al. · 2021 [cited by applicant]
US 11141474B2 · Rauch et al. · 2021 [cited by applicant]
US 11141476B2 · Rauch · 2021 [cited by applicant]
US 11149278B2 · Thess et al. · 2021 [cited by applicant]
US 11179337B2 · Eber et al. · 2021 [cited by applicant]
US 11225682B2 · Reichert et al. · 2022 [cited by applicant]
US 11241493B2 · Rauch et al. · 2022 [cited by applicant]
US 11248223B2 · Yazdan Panah et al. · 2022 [cited by applicant]
US 11254951B2 · Thess · 2022 [cited by applicant]
US 11266735B2 · Kallen et al. · 2022 [cited by applicant]
US 11268157B2 · von der Mülbe et al. · 2022 [cited by applicant]
US 11274293B2 · Funkner et al. · 2022 [cited by applicant]
US 11279923B2 · Funkner et al. · 2022 [cited by applicant]
US 11286492B2 · Thess et al. · 2022 [cited by applicant]
US 11345920B2 · Thess et al. · 2022 [cited by applicant]
US 20040110295A1 · Punnonen · 2004 [cited by examiner]
US 20050032730A1 · Von der Mulbe et al. · 2005 [cited by applicant]
US 20050059624A1 · Hoerr et al. · 2005 [cited by applicant]
US 20050250723A1 · Hoerr et al. · 2005 [cited by applicant]
US 20060188490A1 · Hoerr et al. · 2006 [cited by applicant]
US 20080025944A1 · Hoerr et al. · 2008 [cited by applicant]
US 20080267873A1 · Hoerr et al. · 2008 [cited by applicant]
US 20090093433A1 · Woolf et al. · 2009 [cited by applicant]
US 20090324584A1 · Hoerr et al. · 2009 [cited by applicant]
US 20100048883A1 · Ketterer et al. · 2010 [cited by applicant]
US 20100189729A1 · Hoerr et al. · 2010 [cited by applicant]
US 20100203076A1 · Fotin-Mleczek et al. · 2010 [cited by applicant]
US 20100261227A1 · Cooper · 2010 [cited by examiner]
US 20100291156A1 · Barner et al. · 2010 [cited by applicant]
US 20100305196A1 · Probst et al. · 2010 [cited by applicant]
US 20110053829A1 · Baumhof et al. · 2011 [cited by applicant]
US 20110250225A1 · Fotin-Mleczek et al. · 2011 [cited by applicant]
US 20120021043A1 · Kramps et al. · 2012 [cited by applicant]
US 20120258046A1 · Mutzke · 2012 [cited by applicant]
US 20130129754A1 · Thess et al. · 2013 [cited by applicant]
US 20130142818A1 · Baumhof et al. · 2013 [cited by applicant]
US 20130259879A1 · Baumhof et al. · 2013 [cited by applicant]
US 20130280283A1 · Lorenz et al. · 2013 [cited by applicant]
US 20130295043A1 · Kallen et al. · 2013 [cited by applicant]
US 20130336998A1 · Kallen et al. · 2013 [cited by applicant]
US 20140147454A1 · Chakraborty · 2014 [cited by examiner]
US 20140287022A1 · Fujii et al. · 2014 [cited by applicant]
US 20150037326A1 · Butler-Ransohoff et al. · 2015 [cited by applicant]
US 20150050302A1 · Thess · 2015 [cited by applicant]
US 20150057340A1 · Thess et al. · 2015 [cited by applicant]
US 20150093413A1 · Thess et al. · 2015 [cited by applicant]
US 20150118183A1 · Baumhof · 2015 [cited by applicant]
US 20150118264A1 · Baumhof et al. · 2015 [cited by applicant]
US 20150165006A1 · Thess et al. · 2015 [cited by applicant]
US 20150184195A1 · Thess et al. · 2015 [cited by applicant]
US 20150218554A1 · Thess · 2015 [cited by applicant]
US 20150306249A1 · Baumhof et al. · 2015 [cited by applicant]
US 20150320847A1 · Thess et al. · 2015 [cited by applicant]
US 20160130345A1 · Fotin-Mleczek et al. · 2016 [cited by applicant]
US 20160166668A1 · Kallen et al. · 2016 [cited by applicant]
US 20160166678A1 · Kallen et al. · 2016 [cited by applicant]
US 20160166710A1 · Baumhof · 2016 [cited by applicant]
US 20160166711A1 · Schnee et al. · 2016 [cited by applicant]
US 20160168207A1 · Kramps et al. · 2016 [cited by applicant]
US 20160168227A1 · Kallen et al. · 2016 [cited by applicant]
US 20160235864A1 · Schlake et al. · 2016 [cited by applicant]
US 20160304883A1 · Grund et al. · 2016 [cited by applicant]
US 20160304938A1 · Wochner · 2016 [cited by applicant]
US 20160326575A1 · von der Mülbe · 2016 [cited by applicant]
US 20160331844A1 · Fotin-Mleczek et al. · 2016 [cited by applicant]
US 20170014496A1 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 20170029847A1 · Thess · 2017 [cited by applicant]
US 20170114378A1 · Wochner et al. · 2017 [cited by applicant]
US 20170252430A1 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 20170326225A1 · Rauch et al. · 2017 [cited by applicant]
US 20180125952A1 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 20180126003A1 · Hoerr · 2018 [cited by applicant]
US 20180142275A1 · Roos et al. · 2018 [cited by applicant]
US 20180148727A1 · Grund et al. · 2018 [cited by applicant]
US 20180208957A1 · Roos et al. · 2018 [cited by applicant]
US 20180237786A1 · Schlake et al. · 2018 [cited by applicant]
US 20180237817A1 · Roos et al. · 2018 [cited by applicant]
US 20180296663A1 · Hipp et al. · 2018 [cited by applicant]
US 20180312545A1 · Baumhof et al. · 2018 [cited by applicant]
US 20180371392A1 · Mayer et al. · 2018 [cited by applicant]
US 20190017100A1 · Wochner et al. · 2019 [cited by applicant]
US 20190024096A1 · Schmid et al. · 2019 [cited by applicant]
US 20190049414A1 · Wochner et al. · 2019 [cited by applicant]
US 20190083602A1 · Roos et al. · 2019 [cited by applicant]
US 20190100784A1 · Eber et al. · 2019 [cited by applicant]
US 20190160164A1 · Rauch et al. · 2019 [cited by applicant]
US 20190177714A1 · Kunze et al. · 2019 [cited by applicant]
US 20190185859A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190194760A1 · Koch et al. · 2019 [cited by applicant]
US 20190225971A1 · Williams · 2019 [cited by applicant]
US 20190336608A1 · Baumhof et al. · 2019 [cited by applicant]
US 20190336611A1 · Baumhof et al. · 2019 [cited by applicant]
US 20190343933A1 · Horscroft et al. · 2019 [cited by applicant]
US 20190343942A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190351044A1 · Jasny et al. · 2019 [cited by applicant]
US 20190351047A1 · Jasny et al. · 2019 [cited by applicant]
US 20190381180A1 · Baumhof et al. · 2019 [cited by applicant]
US 20200023076A1 · Fotin-Mleczek et al. · 2020 [cited by applicant]
US 20200085852A1 · Fotin-Mleczek · 2020 [cited by applicant]
US 20200085944A1 · Heidenreich et al. · 2020 [cited by applicant]
US 20200149026A1 · Horscroft et al. · 2020 [cited by applicant]
US 20200163878A1 · Baumhof et al. · 2020 [cited by applicant]
US 20200179526A1 · Baumhof et al. · 2020 [cited by applicant]
US 20200392572A1 · Yazdan Panah et al. · 2020 [cited by applicant]
US 20210030864A1 · Petsch et al. · 2021 [cited by applicant]
US 20210069315A1 · Baumhof et al. · 2021 [cited by applicant]
US 20210162037A1 · Jasny et al. · 2021 [cited by applicant]
US 20210170017A1 · Lutz et al. · 2021 [cited by applicant]
US 20210180106A1 · Wochner et al. · 2021 [cited by applicant]
US 20210205434A1 · Petsch et al. · 2021 [cited by applicant]
US 20210260178A1 · Jasny et al. · 2021 [cited by applicant]
US 20210261897A1 · Yazdan Panah et al. · 2021 [cited by applicant]
US 20210361761A1 · Lutz et al. · 2021 [cited by applicant]
US 20210403925A1 · Chevessier-Tünnesen et al. · 2021 [cited by applicant]
US 20220040281A1 · Schwendt et al. · 2022 [cited by applicant]
US 20220073962A1 · Schwenger et al. · 2022 [cited by applicant]
US 20220133908A1 · Rejman et al. · 2022 [cited by applicant]
US 20220144877A1 · Heinz et al. · 2022 [cited by applicant]
EP 2762165A2 · 2014 [cited by applicant]
EP 3167059 · 2017 [cited by applicant]
EP 3594337 · 2020 [cited by applicant]
EP 3708668A1 · 2020 [cited by applicant]
WO WO1999014346 · 1999 [cited by applicant]
WO WO2001007590 · 2001 [cited by applicant]
WO WO2001014416 · 2001 [cited by applicant]
WO WO2002085434 · 2002 [cited by applicant]
WO WO2002098443 · 2002 [cited by applicant]
WO WO2003059381 · 2003 [cited by applicant]
WO WO2005075644 · 2005 [cited by applicant]
WO WO2007036366 · 2007 [cited by applicant]
WO WO2007068265 · 2007 [cited by applicant]
WO WO2008112127 · 2008 [cited by applicant]
WO WO2009127230 · 2009 [cited by applicant]
WO WO2010037539 · 2010 [cited by applicant]
WO WO2010088927 · 2010 [cited by applicant]
WO WO2011005799 · 2011 [cited by applicant]
WO WO2011069528 · 2011 [cited by applicant]
WO WO2011069587 · 2011 [cited by applicant]
WO WO2011144358 · 2011 [cited by applicant]
WO WO2013090648 · 2013 [cited by applicant]
WO WO2013113501 · 2013 [cited by applicant]
WO WO2013113502 · 2013 [cited by applicant]
WO WO2013113736 · 2013 [cited by applicant]
WO WO2013120626 · 2013 [cited by applicant]
WO WO2013120627 · 2013 [cited by applicant]
WO WO2013120628 · 2013 [cited by applicant]
WO WO2013120629 · 2013 [cited by applicant]
WO WO2013143698 · 2013 [cited by applicant]
WO WO2013143699 · 2013 [cited by applicant]
WO WO2013143700 · 2013 [cited by applicant]
WO WO2013151736 · 2013 [cited by applicant]
WO WO2013174409 · 2013 [cited by applicant]
WO WO2015101415 · 2015 [cited by applicant]
WO WO2016005004 · 2016 [cited by applicant]
WO WO2016005324 · 2016 [cited by applicant]
WO WO2016011306 · 2016 [cited by applicant]
WO WO2016107877 · 2016 [cited by applicant]
WO WO2016165825 · 2016 [cited by applicant]
WO WO2016165831 · 2016 [cited by applicant]
WO WO2016174227 · 2016 [cited by applicant]
WO WO2016174271 · 2016 [cited by applicant]
WO WO2016184575 · 2016 [cited by applicant]
WO WO2016184576 · 2016 [cited by applicant]
WO WO2016184822 · 2016 [cited by applicant]
WO WO2016193206 · 2016 [cited by applicant]
WO WO2016193226 · 2016 [cited by applicant]
WO WO2016203025 · 2016 [cited by applicant]
WO WO2017001058 · 2017 [cited by applicant]
WO WO2017009376 · 2017 [cited by applicant]
WO WO2017021546 · 2017 [cited by applicant]
WO WO2017025120 · 2017 [cited by applicant]
WO WO2017025447 · 2017 [cited by applicant]
WO WO2017036580 · 2017 [cited by applicant]
WO WO2020074642 · 2020 [cited by applicant]
“ [cited by applicant]
Adibzadeh et al., “Enhancing Stability of Destabilized Green Fluorescent Protein Using Chimeric mRNA Containing Human Beta-Globin 5′ and 3′ Untranslated Regions,” [cited by applicant]
Andreani et al., “Orpheovirus IHUMI-LCC2: A New Virus among the Giant Viruses,” [cited by applicant]
Bernstein et al., “The poly(A)-poly(A)-binding protein complex is a major determinant of mRNA stability in vitro,” [cited by applicant]
BioNTech press release “Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19” Dec. 2, 2020. [cited by applicant]
Borman et al., “Free Poly(A) Stimulates Capped mRNA Translation in Vitro through the eIF4G-Poly(A)-binding Protein Interaction” [cited by applicant]
Communication pursuant to Article 94(3) EPC issued in European Application No. 20157801.0, dated Jan. 13, 2022. [cited by applicant]
DiCiommo et al., “Rapid, High Level Protein Production Using DNA-based Semliki Forest Virus Vectors,” [cited by applicant]
Dubensky et al., “Sindbis Virus DNA-Based Expression Vectors: Utility for In Vitro and In Vivo Gene Transfer,” [cited by applicant]
EMBL RPL36A “Homo sapiens RPL36AL mRNA for ribosomal protein L36a-like, complete cds,” Oct. 2, 2002. [cited by applicant]
Expert declaration from Professor Steven Dowdy, dated Feb. 17, 2023. [cited by applicant]
Expert declaration from Utz Fischer, dated Apr. 26, 2023. [cited by applicant]
Felgner et al., “Nomenclature for Synthetic Gene Delivery Systems,” [cited by applicant]
Ferrari et al., “Trends in lipoplex physical properties dependent on cationic lipid structure, vehicle and complexation procedure do not correlate with biological activity,” [cited by applicant]
Gallie et al., “The histone 3′-terminal stem-loop is necessary for translation in Chinese Hamster ovary cells,” [cited by applicant]
Goodwin et al., “The 3′-flanking sequence of the bovine growth hormone gene contains novel elements required for efficient and accurate polyadenylation,” [cited by applicant]
Herweijer, et al., “A Plasmid-Based Self-Amplifying Sindbis Virus Vector,” [cited by applicant]
Holtkamp et al. “Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells,” [cited by applicant]
Iadevaia et al., “All translation elongation factors and the e, f, and h subunits of translation initiation factor 3 are encoded by 5′-terminal oligopyrimidine (TOP) mRNAs,” [cited by applicant]
Khanam et al., “Poly(A)-Binding Protein Binds to A-Rich Sequences via RNA-Binding Domains 1+2 and 3+4,” [cited by applicant]
Ledda et al., “Effect of 3′UTR length on the translational regulation of 5′-terminal oligopyrimidine mRNAs,” [cited by applicant]
Li et al., “Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and in vivo,” [cited by applicant]
McCutchan et al., “Enhancement of the Infectivity of Simian Virus 40 Deoxyribonucleic Acid With Diethylaminoethyl-Dextran,” [cited by applicant]
Milone et al., “Characterization of deadenylation in trypanosome extracts and its inhibition by poly(A)-binding protein Pablp,” [cited by applicant]
Mockey et al., “mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level,” [cited by applicant]
NCBI—protein blast against viral proteins using the sequence “SIINFEKL,” dated Apr. 10, 2023. [cited by applicant]
Office Action issued in European Application No. 20157801.0, mailed Jan. 13, 2022. [cited by applicant]
Office Action issued in U.S. Appl. No. 15/534,496, mailed Aug. 20, 2019. [cited by applicant]
Office Action issued in U.S. Appl. No. 15/534,496, mailed Feb. 6, 2019. [cited by applicant]
Office Action issued in U.S. Appl. No. 15/534,496, mailed Jun. 24, 2020. [cited by applicant]
Office Action issued in U.S. Appl. No. 15/534,496, mailed Jan. 4, 2021. [cited by applicant]
Office Action issued in U.S. Appl. No. 15/534,496, mailed Sep. 6, 2018. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/408,332, mailed Jan. 19, 2022. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/408,332, mailed Feb. 24, 2022. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/542,430, mailed Mar. 7, 2022. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/542,430, mailed Mar. 31, 2022. [cited by applicant]
Opposition against EP 3 708 668, submission of opponent 1 (Pfizer Inc.), dated Apr. 27, 2023. [cited by applicant]
Opposition against EP 3 708 668, submission of opponent 2 (BioNTech SE), dated Apr. 27, 2023. [cited by applicant]
Opposition against EP 3 708 668, submission of opponent 3 (Sanofi), dated Apr. 26, 2023. [cited by applicant]
Opposition against EP 3 708 668, submission of opponent 4 (Cooley (UK) LLP), dated Apr. 27, 2023. [cited by applicant]
Pandey & Marzluff, “The Stem-Loop Structure at the 3′ End of Histone mRNA is Necessary and Sufficient for Regulation of Histone mRNA Stability,” [cited by applicant]
PCT International Preliminary Report on Patentability issued in corresponding PCT Application No. PCT/EP2015/002501, mailed on Jun. 13, 2017. [cited by applicant]
PCT International Search Report and Written Opinion issued in corresponding PCT Application No. PCT/EP2015/002501, mailed on Mar. 5, 2016. [cited by applicant]
Polo et al., “Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors,” [cited by applicant]
Response to Official Communication in European Application No. 20157801.0, filed May 23, 2022. [cited by applicant]
Sachs, “The role of poly(A) in the translation and stability of mRNA,” [cited by applicant]
Sahin et al., “mRNA-based therapeutics—developing a new class of drugs,” [cited by applicant]
Schlake et al., “Developing mRNA-vaccine technologies,” [cited by applicant]
Search Report issued in European Application No. 20157801.0, dated Aug. 13, 2020. [cited by applicant]
Supplementary Experimental Results PpLuc expression from mRNA intradermal administration, Feb. 17, 2023. [cited by applicant]
Supplementary Experimental Results pPLuc expression from mRNA transfection, Feb. 17, 2023. [cited by applicant]
Supplementary Experimental Results Spike protein expression from mRNA intramuscular administration, Feb. 17, 2023. [cited by applicant]
Trepotec et al., “Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life,” RNA, 25:507-518, 2019. [cited by applicant]
Weissman, “mRNA transcript therapy,” [cited by applicant]
Zhao et al., “Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor,” [cited by applicant]
Expert declaration from Professor Utz Fischer, dated Jul. 2, 2023. [cited by applicant]
Brito et al., “A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines,” Molecular Therapy 22:2118-2129, 2014. [cited by applicant]
Conry et al., “Characterization of a Messenger RNA Polynucleotide Vaccine Vector,” Cancer Research 55:1397-1400, 1995. [cited by applicant]
Cook et al., “Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults,” Vaccine 24:2395-2402, 2006. [cited by applicant]
Diez-Domingo et al., “Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged≥50 years: A randomised non-inferiority clinical trial,” Vaccine 33:789-795, 201… [cited by applicant]
Expert declaration from Professor G.T. Rijkers, dated Jun. 15, 2023. [cited by applicant]
Fisch et al., “Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route,” Vaccine 14:1132-1136, 1996. [cited by applicant]
Fleeton et al., “Self-replicative RNA vaccines elicit protection against Influenza A Virus, Respiratory Syncytial Virus, and a Tickborne Encephalitis Virus,” Journal of Infectious Diseases 183:1395-1398, 2001. [cited by applicant]
Gillet et al., “Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injec… [cited by applicant]
Hopf et al., “Comparable immune responsiveness but increased reactogenicity after subcutaneous versus intramuscular administration of tick borne encephalitis (TBE) vaccine,” Vaccine 34:2027-2034, 2016. [cited by applicant]
Kariko et al., “Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA,” Immunity 23:165-175, 2005. [cited by applicant]
Kormann et al., “Expression of therapeutic proteins after delivery of chemically modified mRNA in mice,” Nature Biotechnology 29:154-157 and online materials, 2011. [cited by applicant]
Li et al., “Intravenous injection of Coronavirus Disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in mouse model,” Clinical Infectious Diseases 74:1933-1950, 2022. [cited by applicant]
Mark et al., “Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents,” Vaccine 17:2067-2072, 1999. [cited by applicant]
Michaels et al., “Injection granuloma of the buttock,” C.M.A. Journal 102:626-628, 1970. [cited by applicant]
Mitragotri, “Immunization without needles,” Nature Reviews Immunology 5:905-916, 2005. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/713,533, mailed Jun. 23, 2023. [cited by applicant]
Pardi et al., “Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses,” J. Exp. Med., 215:1571-1588, 2018. [cited by applicant]
Pardi et al., “Zika virus protection by a single low dose nucleoside modified mRNA vaccination,” Nature 543:248-251, 2017. [cited by applicant]
Public Health England. Immunisation procedures: the green book, chapter 4. Available at: www.gov.uk/government/uploads/system/uploads/attachment_data/file/147915/Green-Book-Chapter-4.pdf Published date: Mar. 2013. [cited by applicant]
Saleh et al., “Vaccine development throughout history,” Cureus 13:e16635, 2021. [cited by applicant]
Wolff et al., “Direct Gene Transfer into Mouse Muscle in Vivo,” Science 247:1465-1468, 1990. [cited by applicant]
Zuckerman, “The importance of injecting vaccines into muscle,” BMJ 321:1237-1238, 2000. [cited by applicant]
Expert declaration from Professor Utz Fischer, dated Oct. 11, 2023. (30 pages). [cited by applicant]
Extract of Chapter 1 of Barrera-Saldaña (2012), Genetic Engineering—Basics, New Applications and Responsibilities, ISBM 978-953-307-790-1. (8 pages). [cited by applicant]
Gingold et al., “A Dual Program for Translation Regulation in Cellular Proliferation and Differentiation,” Cell 158:1281-1292, 2014. [cited by applicant]
Huarte et al., “Transient Translational Silencing by Reversible mRNA Deadenylation,” Cell 69:1021-1030, 1992. [cited by applicant]
Moreira, “Integrating transcription kinetics with alternative polyadenylation and cell cycle control,” Nucleus 2:556-561, 2011. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/713,533, mailed Jul. 26, 2023. [cited by applicant]
Opposition against EP 3 708 668, submission of Opponent 2 (BioNTech SE), dated Aug. 7, 2023. (18 pages). [cited by applicant]
Opposition against EP 3 708 668, submission of Opponent 2 (BioNTech SE), dated Oct. 23, 2023. (8 pages). [cited by applicant]
Opposition against EP 3 708 668, submission of Proprietor, dated Aug. 2, 2023. (63 pages). [cited by applicant]
Opposition against EP 3 708 668, submission of Proprietor, dated Sep. 14, 2023. (70 pages). [cited by applicant]
Opposition against EP 3 708 668, submission of Proprietor, dated Oct. 6, 2023. (15 pages). [cited by applicant]
Opposition against EP 3 708 668, submission of Proprietor, dated Nov. 2, 2023. (15 pages). [cited by applicant]
Opposition against EP 3 708 668, submission of Proprietor, dated Jan. 18, 2024. (9 pages). [cited by applicant]
Opposition against EP 4 023 755, submission of Opponent 1 (BioNTech SE), dated Dec. 6, 2023. (59 pages). [cited by applicant]
Opposition against EP 4 023 755, submission of Opponent 2 (Pfizer Inc.), dated Jan. 26, 2024. (79 pages). [cited by applicant]
Opposition against EP 4 023 755, submission of Opponent 3 (Sanofi), dated Jan. 26, 2024. (18 pages). [cited by applicant]
Opposition against EP 4 023 755, submission of Opponent 4 (Cooley (UK) LLP), dated Jan. 26, 2024. (71 pages). [cited by applicant]
Pascolo, “Vaccination with messenger RNA (mRNA),” Handb Exp Pharmacol. 183:221- 235, 2008. [cited by applicant]
Petsch et al., “Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection,” Nat Biotechnol. 30:1210-1216, 2012. [cited by applicant]
Protein translation of SEQ ID No. 124 from EP 2 762 165 A2. [cited by applicant]
Proudfoot, “Ending the message: poly(A) signals then and now,” Genes Dev. 25:1770-1782, 2011. [cited by applicant]
Response to Official Communication in European Application No. 21209125.0, filed Feb. 2, 2023. (16 pages). [cited by applicant]
Uniprot, “P15941 MUC1_Human”, Nov. 16, 2014, version 168. [cited by applicant]
Yonaha & Proudfoot, “Transcriptional termination and coupled polyadenylation in vitro,” The EMBO Journal, 19:3770-3777, 2000. [cited by applicant]
Admission of CureVac concerning the data generated by the University of Salzburg, dated Feb. 28, 2024, as filed with the High Court of Justice, Case No. HP-2022-000023. (3 pages). [cited by applicant]
Biontech's Corrected Reply to Notice of Experiments, dated Apr. 23, 2024, as filed with the High Court of Justice, Case No. HP-2022-000023. (21 pages). [cited by applicant]
Biontech's Reply to Notice of Experiments, dated Apr. 23, 2024, as filed with the High Court of Justice, Case No. HP-2022-000023. (20 pages). [cited by applicant]
Expert declaration from Professor Daniel Herschlag, filed in Oppositions against EP 3 708 668 and EP 4 023 755, dated May 19, 2024. (92 pages). [cited by applicant]
Expert declaration from Professor Daniel Herschlag, filed in Oppositions against EP 3 708 668 and EP 4 023 755, dated Jun. 4, 2024 (3 pages). [cited by applicant]
Expert declaration from Professor Dr. Jorg Vogel, filed in Opposition against EP 3 708 668, dated Mar. 27, 2024. (15 pages). [cited by applicant]
Expert declaration from Professor Meisner-Kober, filed in Opposition against EP 3 708 668, dated Mar. 21, 2024. (12 pages). [cited by applicant]
Firdessa-Fite et al., “Promising Non-Viral Vector for Efficient and Versatile Delivery of mRNA for Antigen-Specific Immunotherapy,” Cell and Gene Therapy Insights, 6:1399-1409, 2020. [cited by applicant]
Gustafsson et al., “Codon bias and heterologous protein expression,” Trends Biotechnol 22(7):346-353, 2004. [cited by applicant]
In vivo-jetPEI Product Website, as captured from https://www.polyplus-sartorius.com/products/in-vivo-jetpei#simple-2 on May 28, 2024. (18 pages). [cited by applicant]
Judgement of The High Court of Justice, Case No. HP-2022-000023, dated Oct. 8, 2024. (111 pages). [cited by applicant]
Kariko et al., “Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translation capacity and biological stability,” Mol Ther. 16:1833-1840, 2008. [cited by applicant]
Karikó et al., “Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin,” Mol. Ther. 20(5):948-953, 2012. [cited by applicant]
McCarthy et al., “Aerosolized Pulmonary Delivery of mRNA Constructs Attenuates Severity of [cited by applicant]
Nagata et al., “Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells: analysis of plasmid DNA encoding a CTL epitope derived from microorganisms,” Biochem. Biophys. Res. Commun. 261:44… [cited by applicant]
Opposition against EP 3 708 668, Preliminary Opinion of the Opposition Division, dated Jul. 1, 2024. (29 pages). [cited by applicant]
Opposition against EP 3 708 668, submission of Opponent 2 (BioNTech SE), dated Mar. 27, 2024. (8 pages). [cited by applicant]
Opposition against EP 3 708 668, submission of Opponent 2 (BioNTech SE), dated Apr. 26, 2024. (5 pages). [cited by applicant]
Opposition against EP 3 708 668, submission of Opponent 2 (BioNTech SE), dated May 31, 2024. (21 pages). [cited by applicant]
Opposition against EP 3 708 668, submission of Proprietor, dated May 21, 2024. (5 pages). [cited by applicant]
Opposition against EP 3 708 668, submission of Proprietor, dated Jun. 11, 2024. (2 pages). [cited by applicant]
Opposition against EP 4 023 755, Preliminary Opinion of the Opposition Division, dated Jul. 24, 2024. (29 pages). [cited by applicant]
Opposition against EP 4 023 755, Reply of Proprietor to the notice(s) of opposition, dated Mar. 28, 2024. (79 pages). [cited by applicant]
Opposition against EP 4 023 755, submission of Opponent 1 (BioNTech SE), dated May 2, 2024. (10 pages). [cited by applicant]
Opposition against EP 4 023 755, submission of Opponent 1 (BioNTech SE), dated May 31, 2024. (21 pages). [cited by applicant]
Opposition against EP 4 023 755, submission of Proprietor, dated Jun. 7, 2024. (81 pages). [cited by applicant]
Patentee's Submission with experimental data, dated Jan. 25, 2024, as filed with the High Court of Justice, Case No. HP-2022-000023. (94 pages). [cited by applicant]
Rabinovich (Ed.), “Synthetic Messenger RNA and Cell Metabolism Modulation,” [cited by applicant]
Riley et al., “Ionizable Lipid Nanoparticles for in Utero mRNA Delivery,” Science Advances, 7:eaba1028, pp. 1-15, 2021. [cited by applicant]
Sultana et al., “Optimizing Cardiac Delivery of Modified mRNA,” Molecular Therapy 25: 1306-1615, 2017. [cited by applicant]
Wikipedia, “Ovalbumin”, Mar. 28, 2024. (3 pages). [cited by applicant]
“Cell-based expression assay,” Experimental results, submitted in Opposition against European Patent 3 708 668, Jan. 24, 2025. (5 pages). [cited by applicant]
“In vivo imaging of reporter protein expression after I.M. administration,” Experimental Data from the University of Salzburg, dated Jan. 23, 2025. (5 pages). [cited by applicant]
Declaration of Andreas Thess, submitted in Opposition against European Patent 3 708 668, dated Jan. 24, 2025. (1 page). [cited by applicant]
German original of an internal communication at CureVac concerning Examination Proceedings, and English translation, submitted in Opposition against European Patent 3 708 668, dated Jan. 24, 2025. (6 pages). [cited by applicant]
Kuhn et al., mRNA as a versatile tool for exogenous protein expression, » [cited by applicant]
Lim et al., “Mixed tailing by TENT4A and TENT4B shields mRNA from rapid deadenylation,” Science, 361:701-704, 2018. [cited by applicant]
Opposition against EP 3 708 668, submission by Opponent BioNTech SE, dated Jan. 24, 2025. (41 pages). [cited by applicant]
Opposition against EP 3 708 668, submission by Opponent Pfizer Inc., dated Jan. 24, 2025. (30 pages). [cited by applicant]
Opposition against EP 3 708 668, submission by Opponent Sanofi, dated Jan. 24, 2025. (14 pages). [cited by applicant]
Opposition against EP 3 708 668, submission by Proprietor Cure Vac SE, dated Jan. 24, 2025. (18 pages). [cited by applicant]
Opposition against EP 3 708 668, submission by Proprietor Cure Vac SE, dated Feb. 26, 2025. (59 pages). [cited by applicant]
Expert declaration from Andreas Theß, filed in Opposition against EP 4 023 755, dated Feb. 24, 2025. (4 pages). [cited by applicant]